- Home
- BUD vs GILD Comparison
BUD vs GILD Comparison
Compare BUD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BUD | GILD |
|---|---|---|
| Founded | 1366 | 1987 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.0B | 180.6B |
| IPO Year | 2016 | 2003 |
Fundamental Metrics
Financial Performance| Metric | BUD | GILD |
|---|---|---|
| Price | $75.06 | $147.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 28 |
| Target Price | $95.62 | ★ $159.27 |
| AVG Volume (30 Days) | 2.1M | ★ 4.8M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | 1.09% | ★ 2.27% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,689,000,000.00 |
| Revenue This Year | $9.09 | $4.31 |
| Revenue Next Year | $3.92 | $6.53 |
| P/E Ratio | $23.27 | ★ N/A |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $58.82 | $114.02 |
| 52 Week High | $86.60 | $157.29 |
Technical Indicators
Market Signals| Indicator | BUD | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 50.12 |
| Support Level | $71.57 | $142.99 |
| Resistance Level | $81.15 | $152.04 |
| Average True Range (ATR) | 1.12 | 3.45 |
| MACD | -0.20 | -0.94 |
| Stochastic Oscillator | 34.89 | 40.05 |
Price Performance
Historical ComparisonAbout BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the top five consumer product companies by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 acquired SABMiller.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).